LU90856I2 - Uprima - apomorphine hydrochloride et ses d-riv-s pharmaceutiquement acceptables - Google Patents

Uprima - apomorphine hydrochloride et ses d-riv-s pharmaceutiquement acceptables

Info

Publication number
LU90856I2
LU90856I2 LU90856C LU90856C LU90856I2 LU 90856 I2 LU90856 I2 LU 90856I2 LU 90856 C LU90856 C LU 90856C LU 90856 C LU90856 C LU 90856C LU 90856 I2 LU90856 I2 LU 90856I2
Authority
LU
Luxembourg
Prior art keywords
uprima
pharmaceutically acceptable
acceptable derivatives
apomorphine hydrochloride
apomorphine
Prior art date
Application number
LU90856C
Other languages
English (en)
Original Assignee
Pentech Pharmaceuticals Inc
Univ Kingston
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22868404&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU90856(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pentech Pharmaceuticals Inc, Univ Kingston filed Critical Pentech Pharmaceuticals Inc
Publication of LU90856I2 publication Critical patent/LU90856I2/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
LU90856C 1994-04-22 2001-11-23 Uprima - apomorphine hydrochloride et ses d-riv-s pharmaceutiquement acceptables LU90856I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23125094A 1994-04-22 1994-04-22
PCT/US1995/004897 WO1995028930A1 (fr) 1994-04-22 1995-04-21 Formes galeniques et procede de traitement du dysfonctionnement de l'erection masculine

Publications (1)

Publication Number Publication Date
LU90856I2 true LU90856I2 (fr) 2002-01-24

Family

ID=22868404

Family Applications (1)

Application Number Title Priority Date Filing Date
LU90856C LU90856I2 (fr) 1994-04-22 2001-11-23 Uprima - apomorphine hydrochloride et ses d-riv-s pharmaceutiquement acceptables

Country Status (16)

Country Link
US (3) US5770606A (fr)
EP (2) EP0978282B1 (fr)
JP (1) JP3310982B2 (fr)
KR (1) KR100374924B1 (fr)
AT (2) ATE312609T1 (fr)
AU (1) AU703608B2 (fr)
CA (1) CA2188385C (fr)
DE (3) DE69514794T2 (fr)
DK (2) DK0978282T3 (fr)
ES (2) ES2256999T3 (fr)
GR (1) GR3033084T3 (fr)
HK (2) HK1014239A1 (fr)
LU (1) LU90856I2 (fr)
NL (1) NL300072I1 (fr)
PT (1) PT758895E (fr)
WO (1) WO1995028930A1 (fr)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6143746A (en) * 1994-01-21 2000-11-07 Icos Corporation Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use
US6395744B1 (en) 1994-04-22 2002-05-28 Queen's University At Kingston Method and compositions for the treatment or amelioration of female sexual dysfunction
US6121276A (en) * 1994-04-22 2000-09-19 Pentech Pharmaceuticals, Inc. Apomorphine-containing dosage forms for ameliorating male erectile dysfunction
US20020165122A1 (en) * 1994-04-22 2002-11-07 Heaton Jeremy P. W. Method and compositions for the treatment or amelioration of female sexual dysfunction
US6566368B2 (en) * 1994-04-22 2003-05-20 Pentech Pharmaceuticals, Inc. Apomorphine-containing dosage form for ameliorating male erectile dysfunction
US5624677A (en) * 1995-06-13 1997-04-29 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
AU751565B2 (en) * 1995-06-13 2002-08-22 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
US5888534A (en) * 1995-06-13 1999-03-30 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
GB9514473D0 (en) * 1995-07-14 1995-09-13 Glaxo Lab Sa Chemical compounds
US20050065161A1 (en) * 1996-02-02 2005-03-24 Nitromed, Inc. Nitrosated and nitrosylated alpha-adrenergic receptor antagonist compounds, compositions and their uses
EP0834308A1 (fr) * 1996-09-30 1998-04-08 LG Chemical Limited Formulation ophtalique pour le traitement de la myopie contenant un agoniste de la dopamine et cyclodextrine
DE19652268C2 (de) * 1996-12-16 2000-06-29 Lohmann Therapie Syst Lts Arzneizubereitung für die Freisetzung von Apomorphin in der Mundhöhle
GB9700878D0 (en) 1997-01-17 1997-03-05 Scherer Ltd R P Dosage forms and method for ameliorating male erectile dysfunction
US6043252A (en) * 1997-05-05 2000-03-28 Icos Corporation Carboline derivatives
EP0996447B1 (fr) * 1997-05-19 2006-07-19 Zonagen, Inc. Therapie combinatoire permettant de moduler la reponse sexuelle chez un patient
IL132993A0 (en) * 1997-05-29 2001-03-19 Mochida Pharm Co Ltd Therapeutic agent for erection failure
AU742787B2 (en) 1997-07-09 2002-01-10 Androsolutions, Inc. Improved methods and compositions for treating male erectile dysfunction
US6103765A (en) * 1997-07-09 2000-08-15 Androsolutions, Inc. Methods for treating male erectile dysfunction
US6472425B1 (en) 1997-10-31 2002-10-29 Nitromed, Inc. Methods for treating female sexual dysfunctions
AU751182B2 (en) * 1997-12-02 2002-08-08 Archimedes Development Limited Compositions for nasal administration
US5945117A (en) * 1998-01-30 1999-08-31 Pentech Pharmaceuticals, Inc. Treatment of female sexual dysfunction
US6403605B1 (en) * 1998-05-29 2002-06-11 Queen's University At Kingston Methods for the normalization of sexual response and amelioration of long term genital tissue degradation
AU2003204720B2 (en) * 1998-05-29 2006-06-29 Tap Pharmaceutical Products Inc. Methods for the normalization of sexual response and amelioration of long term genital tissue degradation
US6436950B1 (en) 1998-08-14 2002-08-20 Nastech Pharmaceutical Company, Inc. Nasal delivery of apomorphine
US20020002175A1 (en) * 2000-09-19 2002-01-03 Charanjit Behl Nasal delivery of apomorphine in combination with glycol derivatives
US5994363A (en) * 1998-08-24 1999-11-30 Pentech Pharmaceuticals, Inc. Amelioration of apomorphine adverse effects
US20040063719A1 (en) * 1998-08-26 2004-04-01 Queen's University At Kingston Combination therapy using antihypertensive agents and endothelin antagonists
WO2000012110A2 (fr) 1998-08-26 2000-03-09 Queen's University At Kingston Methodes de remodelisation des voies neuronales et cardiovasculaires
US6291471B1 (en) * 1998-12-17 2001-09-18 Abb Holdings, Inc. Use of apomorphine for the treatment of organic erectile dysfunction in males
US6455564B1 (en) 1999-01-06 2002-09-24 Pharmacia & Upjohn Company Method of treating sexual disturbances
US6552024B1 (en) 1999-01-21 2003-04-22 Lavipharm Laboratories Inc. Compositions and methods for mucosal delivery
AU3490300A (en) * 1999-03-12 2000-10-04 Nitromed, Inc. Dopamine agonists in combination with nitric oxide donors, compositions and methods of use
US6087362A (en) * 1999-03-16 2000-07-11 Pentech Pharmaceuticals, Inc. Apomorphine and sildenafil composition
US7577475B2 (en) * 1999-04-16 2009-08-18 Cardiocom System, method, and apparatus for combining information from an implanted device with information from a patient monitoring apparatus
US7258850B2 (en) * 1999-05-04 2007-08-21 Aradigm Corporation Methods and compositions for treating erectile dysfunction
DK1225881T3 (da) 1999-09-03 2006-06-12 Apbi Holdings Llc Anvendelsen af dapoxetin, en hurtigt-virkende selektiv serotonin genoptagelseshæmmer, til behandling af seksuel dysfunktion
CN1471395A (zh) * 2000-04-07 2004-01-28 ����ҽҩƷ���޹�˾ 阿扑吗啡衍生物及其使用方法
AU2001278981A1 (en) * 2000-07-21 2002-02-05 Tom F Lue Prevention and treatment of sexual arousal disorders
US7223406B2 (en) * 2000-07-21 2007-05-29 The Regents Of The University Of California Methods and compositions for preventing and treating male erectile dysfunction and female sexual arousal disorder
FR2813193B1 (fr) * 2000-08-25 2003-08-15 Pelvipharm Medicament pour le traitement des dysfonctions sexuelles par action sur le systeme nerveux central
US6503894B1 (en) 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
EP1341536A4 (fr) 2000-11-15 2007-08-01 Tap Pharmaceutical Prod Inc Traitement d'un dysfonctionnement sexuel entraine par une medication antidepressive par apomorphine
US20020103105A1 (en) * 2000-11-22 2002-08-01 Brioni Jorge D. Use of selective dopamine D4 receptor agonists for treating sexual dysfunction
EP1224933A1 (fr) * 2001-01-19 2002-07-24 Sanofi-Synthelabo Nouvelle combinaison d'actifs avec alfuzosine et apomorphine
EP1365740A1 (fr) * 2001-02-08 2003-12-03 Pharmacia Corporation Medicament a action rapide pour le traitement de dysfonctionnements sexuels
US20030187011A1 (en) * 2001-12-20 2003-10-02 Lashuel Hilal A. Apomorphine inhibitors of amyloid-beta (Abeta) fibril formation and their use in amyloidosis based disease
NZ534340A (en) * 2002-02-07 2006-04-28 Pharmacia Corp Pharmaceutical dosage form for mucosal delivery
BR0308567A (pt) * 2002-03-19 2007-01-09 Michael Holick derivados de glicosìdeo e glicosìdeo de ortoéster de apomorfina, análogos, e seus usos
US7736665B2 (en) * 2002-05-31 2010-06-15 Titan Pharmaceuticals, Inc. Implantable polymeric device for sustained release of buprenorphine
GB0221711D0 (en) * 2002-09-19 2002-10-30 Ardana Bioscience Ltd Methods
CA2445212A1 (fr) * 2002-10-10 2004-04-10 Queen's University At Kingston Traitement de la dysfonction sexuelle
GB0304636D0 (en) * 2003-02-28 2003-04-02 Britannia Pharmaceuticals Ltd Pharmaceutical composition for nasal delivery
US7943632B2 (en) * 2003-03-17 2011-05-17 Neurohealing Pharmaceuticals, Inc. High potency dopaminergic treatment of neurological impairment associated with brain injury
KR101152183B1 (ko) 2003-03-31 2012-06-15 타이탄 파머슈티컬즈 인코퍼레이티드 도파민 아고니스트의 지속 방출을 위한 이식가능한 폴리머디바이스
US20040204439A1 (en) * 2003-04-14 2004-10-14 Staniforth John Nicholas Composition, device, and method for treating sexual dysfunction via inhalation
EP1613323A1 (fr) * 2003-04-14 2006-01-11 Vectura Limited Compositions pharmaceutiques comprenant de l'apomorphine pour l'inhalation pulmonaire
NZ544180A (en) * 2003-06-17 2009-01-31 Janssen Pharmaceutica Nv Substituted spirobenzazepines
ZA200803087B (en) 2005-10-12 2009-11-25 Unimed Pharmaceuticals Llc Improved testosterone gel and method of use
US20070173490A1 (en) * 2006-01-20 2007-07-26 Lian Huang Novel solid forms of (4R)-1-[2-chloro-5-fluorobenzoyl)amino-3-methoxybenzoyl]-1,2,3,5- tetrahydro-spiro[4h-1-benzazepine-4,1'-[2]cyclopentene]-3'-carboxylic acid
GB2437488A (en) * 2006-04-25 2007-10-31 Optinose As Pharmaceutical oily formulation for nasal or buccal administration
GB0721394D0 (en) * 2007-10-31 2007-12-12 Vectura Group Plc Compositions for trating parkinson's disease
DK2952191T3 (en) 2009-06-12 2018-12-10 Sunovion Pharmaceuticals Inc Sublingual apomorphine
CA3115378A1 (fr) 2010-12-16 2012-06-21 Sunovion Pharmaceuticals Inc. Films sublinguaux comprenant de l'apomorphine et une base organique
KR20160108828A (ko) * 2013-11-11 2016-09-20 임팩스 라보라토리즈, 인코포레이티드 신속하게 붕괴되는 제형 및 사용 방법
WO2015191931A1 (fr) * 2014-06-12 2015-12-17 University Of Notre Dame Du Lac Composition et méthode de traitement de maladies neurologiques et de lésions cérébrales
EP3285771A4 (fr) 2015-04-21 2018-12-05 Sunovion Pharmaceuticals Inc. Méthodes de traitement de la maladie de parkinson par l'administration d'apomorphine à une muqueuse orale
CA3128973A1 (fr) 2019-03-04 2020-09-10 Bhaskar Bhattacharyya Compression et communication de donnees a l'aide d'un apprentissage automatique

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2818855A (en) * 1954-02-11 1958-01-07 Anthony P Miller Surgical device
US4127118B1 (en) * 1977-03-16 1995-12-19 Alvaro Latorre Method of effecting and enhancing an erection
US4543256A (en) * 1982-03-17 1985-09-24 Northeastern University (-)-10,1L Methylenedioxy-N-N-propylnoraporphine and methods employing it for inhibiting the effects of epileptic seizures and for prevention and treatment of duodenal ulcers
US4687773A (en) * 1983-03-28 1987-08-18 Mclean Hospital (+)-N-N-propylnorapomorphine and selective limbic activity
US4521421A (en) * 1983-09-26 1985-06-04 Eli Lilly And Company Treatment of sexual dysfunction
US4727064A (en) * 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
US4801587A (en) * 1987-03-02 1989-01-31 Gene Voss Impotence ointment
US5242391A (en) * 1990-04-25 1993-09-07 Alza Corporation Urethral insert for treatment of erectile dysfunction
US5270323A (en) * 1990-05-31 1993-12-14 Pfizer Inc. Method of treating impotence
US5324718A (en) * 1992-07-14 1994-06-28 Thorsteinn Loftsson Cyclodextrin/drug complexation
AU6428894A (en) * 1993-03-26 1994-10-24 Franciscus W.H.M. Merkus Pharmaceutical compositions for intranasal administration of dihydroergotamine, apomorphine and morphine

Also Published As

Publication number Publication date
CA2188385C (fr) 2000-07-11
EP0978282A2 (fr) 2000-02-09
DE10199068I1 (de) 2003-06-05
DE10199068I2 (de) 2004-05-06
DK0978282T3 (da) 2006-04-10
US5985889A (en) 1999-11-16
EP0758895A4 (fr) 1997-04-09
EP0758895B1 (fr) 2000-01-26
AU2295895A (en) 1995-11-16
DE69534693T2 (de) 2006-08-31
GR3033084T3 (en) 2000-08-31
JP3310982B2 (ja) 2002-08-05
ES2256999T3 (es) 2006-07-16
EP0758895A1 (fr) 1997-02-26
DE69534693D1 (de) 2006-01-19
PT758895E (pt) 2000-05-31
WO1995028930A1 (fr) 1995-11-02
ATE189121T1 (de) 2000-02-15
DK0758895T3 (da) 2000-06-13
AU703608B2 (en) 1999-03-25
KR100374924B1 (ko) 2003-07-22
NL300072I1 (nl) 2002-02-01
DE69514794D1 (de) 2000-03-02
ES2143049T3 (es) 2000-05-01
HK1025742A1 (en) 2000-11-24
KR970702041A (ko) 1997-05-13
ATE312609T1 (de) 2005-12-15
US6200983B1 (en) 2001-03-13
DE69514794T2 (de) 2000-07-27
US5770606A (en) 1998-06-23
EP0978282A3 (fr) 2000-06-07
JPH09512273A (ja) 1997-12-09
CA2188385A1 (fr) 1995-11-02
EP0978282B1 (fr) 2005-12-14
HK1014239A1 (en) 1999-09-24

Similar Documents

Publication Publication Date Title
LU90856I2 (fr) Uprima - apomorphine hydrochloride et ses d-riv-s pharmaceutiquement acceptables
ES2188584T3 (es) Derivados heterociclicos de amina.
TR200101335T2 (tr) İktidarsızlık tedavisi için pirazolopirimidinon türevleri
MY103352A (en) Piperazinyl-heterocyclic compounds
BG103945A (en) Derivatives of 4"-substituted-9-deoxo-9a-aza-9a-homoerythromycin a
HUP9802221A2 (hu) Parazitaellenes hatású markfortin- és paraherkvamidszármazékok
MY115662A (en) Novel compounds with analgesic effect
DE69925133D1 (de) Pyrrolobenzodiazepine
NZ240230A (en) Mercaptoacetylamide derivatives; preparation, use and pharmaceutical compositions thereof
EP0896533A4 (fr) Pentafluorobenzenesulfonamides et analogues
FI972308A (fi) 2-substituoituja 1,2,5-tiadiatsolidin-3-oni-1,1-dioksideja ja niitä sisältäviä koostumuksia ja menetelmiä niiden käyttämiseksi
NZ212768A (en) 2-substituted-1,3-propylidene diphosphonate derivatives and pharmaceutical compositions
ES2134801T3 (es) Monohidrato de hidrocloruro de tiagabina cristalina, su preparacion y su uso.
DE69631542D1 (de) Neue geranylgeranylderivate, verfahren zu deren herstellung und entsprechende pharmazeutische zusammensetzungen
MX9704034A (es) Derivados y composiciones de 1,1-dioxido de 2-arilcarboniloximetil-1,2,5-tiadiazolidin-3-ona substituido y metodo de uso.
NO940777L (no) Anvendelse av et pregnanderivat
TR200000455T2 (tr) Alzheimer hastalığının tedavisinde fankinonun kullanılması.
TR200001102T2 (tr) İkameli tetrahidropirimidinen türevleri, üretimleri ve kullanımları.
IL118218A0 (en) Terpenoidic derivatives and pharmaceutical compositions containing them
UA37278C2 (uk) Протикашльова фармацевтична композиція для перорального введення
DE69104220D1 (de) Verfahren zur Herstellung von direktkomprimierten, Cephalosporansäure Derivate enthaltendenTabletten.
PT1152762E (pt) Utilizacao de desoxipeganina no tratamento da demencia de alzheimer
DE69330601D1 (de) Serotoninergische ergolin derivate
IT9086204A0 (it) Metodo per la cura dell'impotenza erettiva maschile
ES2052670T3 (es) Utilizacion de derivados de 2-pirimidinil-1-piperazina.